Wall Street Zen Upgrades Sanofi (NASDAQ:SNY) to Buy

Key Points

• Sanofi has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting increased confidence in its stock performance.
• Analysts have set a consensus price target of $62.00 for Sanofi, with a majority rating it as a "buy" or "strong buy."
• Despite a 7% decline in year-over-year revenue, Sanofi reported quarterly earnings of $0.90 per share, just below expectations.

Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

Several other research firms have also commented on SNY. BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Guggenheim reissued a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Sanofi has an average rating of "Buy" and an average target price of $62.00.

Sanofi Price Performance

SNY stock traded up $1.11 during trading on Friday, reaching $46.75. The company's stock had a trading volume of 2,518,877 shares, compared to its average volume of 2,247,996. Sanofi has a 1 year low of $44.73 and a 1 year high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $114.80 billion, a P/E ratio of 11.24, a price-to-earnings-growth ratio of 1.12 and a beta of 0.48. The company's fifty day moving average is $49.10 and its 200-day moving average is $52.10.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.73 EPS. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SNY. Brighton Jones LLC grew its stake in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after buying an additional 1,869 shares during the period. CIBC Private Wealth Group LLC lifted its position in shares of Sanofi by 19.8% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,175 shares of the company's stock worth $156,000 after purchasing an additional 525 shares during the last quarter. National Bank of Canada FI lifted its position in Sanofi by 2.0% in the fourth quarter. National Bank of Canada FI now owns 303,934 shares of the company's stock valued at $14,659,000 after acquiring an additional 6,089 shares during the last quarter. Geode Capital Management LLC lifted its position in Sanofi by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company's stock valued at $12,427,000 after acquiring an additional 2,917 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Sanofi by 4.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 155,078 shares of the company's stock valued at $7,479,000 after acquiring an additional 7,123 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.